Basso, Virginia http://orcid.org/0000-0001-6078-3439
Tran, Dat Q.
Schaal, Justin B.
Tran, Patti
Eriguchi, Yoshihiro http://orcid.org/0000-0002-5803-230X
Ngole, Diana http://orcid.org/0000-0002-1895-8407
Cabebe, Anthony E.
Park, A. young
Beringer, Paul M.
Ouellette, André J.
Selsted, Michael E.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (RO1 AI22931, RO1 AI22931, RO1 AI22931, RO1 AI22931, RO1 AI22931, RO1 AI22931, RO1 AI22931, RO1 AI22931)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 1 August 2019
Accepted: 30 October 2019
First Online: 15 November 2019
Competing interests
: Drs. Selsted (co-founder, chief scientific officer) and D.Q. Tran (scientific director) hold part time appointments with Oryn Therapeutics, LLC which has licensed theta defensin technologies for commercial development. Dr. Selsted receives no income from Oryn Therapeutics but is an equity holder. Dr. Tran is a part time employee of Oryn. The relationship between Oryn Therapeutics and USC is disclosed to and approved by all parties. All other authors declare no competing interests.